. Author manuscript; available in PMC: 2019 Nov 15.

Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2015 Dec 21;16(3):129–138. doi: 10.1016/j.clml.2015.12.007

Table 4.

Efficacy Stratified by Renal Function

Treatment Response	NRF (n = 8)	SRI (n = 9)	ESRD (n = 9)
Best overall response
Stringent complete response	0	1 (11)	0
Complete response	2 (25)	0	0
Very good partial response	1 (13)	4 (44)	1 (11)
Partial response	3 (38)	1 (11)	4 (44)
Minor response	0	3 (33)	2 (22)
Stable disease	1 (13)	0	1 (11)
Progressive disease	0	0	0
Not evaluable	1 (13)	0	1 (11)
ORR (%; 95% Cl)	6 (75; 35–97)	6 (67; 30–93)	5 (56; 21–86)
Renal response^a	0	2 (22)	0

Data presented as n (%), unless otherwise noted.

Abbreviations: CI = confidence interval; ESRD = end-stage renal disease; NRF = normal renal function; ORR = overall response rate; SRI = severe renal impairment.

Minor renal response.